SCHEMBL2497153

SCHEMBL2497153

O=C(c1ccc(F)cc1)c1cn(-c2cccc(-c3cccnc3Cl)c2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.40
NPC1 O15118 3/20 0.40
MAPT P10636 2/20 0.40
DHODH Q02127 1/20 0.37
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CTSA P10619 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
CTNNB1 P35222 1/20 0.35
TCF7L2 Q9NQB0 1/20 0.35
DGAT2 Q96PD7 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SCN9A Q15858 1/20 0.34
MLLT3 P42568 1/20 0.34
MLLT1 Q03111 1/20 0.34
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2499336 0.91 USP2 (0.38) RAB9ANPC1MAPTDHODHSMN1; SMN2
SCHEMBL2498070 0.90 BACE1 (0.35) DHODHKMT2ADGAT2L3MBTL1MLLT3
SCHEMBL2500738 0.88 SCN9A (0.43) RAB9ANPC1KMT2ASMN1; SMN2DGAT2
SCHEMBL2495969 0.87 CYP11B1 (0.39) RAB9ANPC1SMN1; SMN2TUBB4ATUBB
SCHEMBL2503546 0.86 CTSA (0.39) RAB9ANPC1MAPTDHODHKMT2A
SCHEMBL2499485 0.85 SCN9A (0.39) RAB9ANPC1KMT2ASMN1; SMN2DGAT2
SCHEMBL2502794 0.84 CTSA (0.37) RAB9ANPC1MAPTDHODHKMT2A
SCHEMBL2501423 0.84 CTSA (0.40) RAB9ANPC1MAPTDHODHKMT2A
SCHEMBL1887879 0.84 CTSA (0.42) DHODHSMN1; SMN2CTSASCN9AMLLT3
SCHEMBL2494379 0.82 ITGB1 (0.41) KMT2ASMN1; SMN2L3MBTL1MLLT3MLLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030339-B2 Imidazole derivatives for the treatment of anxiety and related diseases NEUROSEARCH A/S (DK) 2011-10-04 US claimed
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases NEUROSEARCH A/S (DK) 2009-09-17 US claimed
EP-1937649-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2008-07-02 EP claimed
WO-2007042546-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2007-04-19 WO claimed
US-8030339-B2 Imidazole derivatives for the treatment of anxiety and related diseases NEUROSEARCH A/S (DK) 2011-10-04 US disclosed
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases NEUROSEARCH A/S (DK) 2009-09-17 US disclosed
EP-1937649-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2008-07-02 EP disclosed
WO-2007042546-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases GABBR1, GABRB2, GABRB3 RAB9A 1662/4885NPC1 906/4885MAPT 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.